0001140361-22-028807.txt : 20220809 0001140361-22-028807.hdr.sgml : 20220809 20220809071157 ACCESSION NUMBER: 0001140361-22-028807 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220809 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220809 DATE AS OF CHANGE: 20220809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVROBIO, Inc. CENTRAL INDEX KEY: 0001681087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 810710585 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38537 FILM NUMBER: 221146360 BUSINESS ADDRESS: STREET 1: 100 TECHNOLOGY SQUARE STREET 2: 6TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617.914.8420 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY SQUARE STREET 2: 6TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AvroBio, Inc. DATE OF NAME CHANGE: 20160729 8-K 1 brhc10040479_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 
FORM 8-K

 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 9, 2022


AVROBIO, INC.
(Exact name of registrant as specified in its charter)


Delaware
001-38537
81-0710585
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

100 Technology Square
Sixth Floor
Cambridge, MA 02139
(Address of principal executive offices, including zip code)
 
(617) 914-8420
(Registrant’s telephone number, including area code)
 
One Kendall Square
Building 300, Suite 201
Cambridge, MA 02139
(Former Name or Former Address, if Changed Since Last Report)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading
symbol(s)
  
Name of each exchange
on which registered
Common Stock, $0.0001 par value per share
  
AVRO
  
Nasdaq Global Select Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company ☒
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02
Results of Operations and Financial Condition.
 
On August 9, 2022, AVROBIO, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations for the three and six months ended June 30, 2022. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
 
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
 
Item 9.01
Financial Statements and Exhibits.
 
(d) Exhibits

Press release issued by AVROBIO, Inc., dated August 9, 2022.
   
104
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    
AVROBIO, INC.
       
Date: August 9, 2022
By:
/s/ Geoff MacKay
       
Geoff MacKay
       
President and Chief Executive Officer


EX-99.1 2 brhc10040479_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1

AVROBIO Reports Second Quarter 2022 Financial Results and
Provides Business Update

Presented positive data from first five patients in Phase 1/2 cystinosis trial1 showing systemic gene therapy effect at the American Society of Gene and Cell Therapy Annual Meeting; all five patients remain off oral cysteamine

Comprehensive Gaucher disease franchise update planned for Q4 2022

Regulatory interactions planned in 2H 2022 to inform clinical development strategies for cystinosis and Gaucher disease type 3

Hunter syndrome program received FDA Orphan Drug Designation (ODD)

Strong balance sheet with cash runway into Q1 2024

CAMBRIDGE, Mass., Aug. 9, 2022 -- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the second quarter ended June 30, 2022 and provided a business update.

“We’ve made significant progress advancing our pipeline this quarter,” said Geoff MacKay, president and CEO of AVROBIO. “We’re thrilled with the ongoing clinical data generated by the first and only gene therapy trial for cystinosis, showing hematopoietic stem cell (HSC) gene therapy’s potential to stabilize or reduce the impact of cystinosis on different tissues throughout the body. We’re preparing for regulatory agency interactions this fall to discuss our clinical development and regulatory strategy for this program, with the intent of initiating a company-sponsored clinical trial in 2023.

“We have multiple milestones planned for the second half of the year that will further inform the advancement of our pipeline. We plan to provide a comprehensive Gaucher disease franchise update in Q4 2022, including new clinical data from our Guard1 Phase 1/2 clinical trial for Gaucher disease type 1, and updates on the clinical development and regulatory strategy for our Gaucher disease type 3 program. In addition, our collaborators continue to make progress toward the initiation of the planned Phase 1/2 clinical trial for Hunter syndrome,” said MacKay.

“More broadly in the gene therapy sector, the Food and Drug Administration (FDA) Advisory Committee unanimously voted in June to recommend approval of two new HSC gene therapies for two distinct genetic disorders, a potentially important milestone for patients and families. We believe the Advisory Committee’s discussions may provide a window into how future HSC gene therapies will be evaluated by the agency with the recognition that each vector-promoter-gene combination has its own benefit/risk profile,” MacKay added.
1 Collaborator-sponsored Phase 1/2 clinical trial of AVR-RD-04 is funded in part by grants to University of California San Diego from the California Institute for Regenerative Medicine (CIRM), Cystinosis Research Foundation (CRF) and National Institutes of Health (NIH)
Program Updates

Presented clinical data on the first five patients dosed in the fully enrolled Phase 1/2 clinical trial for AVR-RD-04 in cystinosis, including new, early data showing key visual motor integration, visual perception and motor coordination measures impacted by cystinosis stabilized or improved post gene therapy, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

•
Early data indicate that post HSC gene therapy, patients have been able to produce functional cystinosin protein throughout the body, as evidenced by measurements of blood, eye, skin and gastrointestinal mucosa, which indicate a reduction in the accumulation of cystine crystals or prevention of further pathological accumulation

•
Sustained engraftment demonstrated by stable vector copy number (VCN) in patients beyond 12 months with all five dosed patients remaining off oral cysteamine post gene therapy

•
Data from the five patients dosed to date indicate no adverse events (AEs) related to drug product. All AEs were related to myeloablative conditioning, stem cell mobilization, underlying disease or pre-existing conditions

•
Collaborator-sponsored Phase 1/2 clinical trial is funded in part by grants to University of California San Diego from the California Institute for Regenerative Medicine (CIRM), Cystinosis Research Foundation (CRF) and National Institutes of Health (NIH)

•
Read full press release here

Received Orphan Drug Designation (ODD) from FDA for AVR-RD-05 for Hunter syndrome (Mucopolysaccharidosis Type II (MPSII))

•
Read full press release here

Presented preclinical data demonstrating that HSC gene therapy significantly reduced accumulation of glycogen in a mouse model of infantile-onset Pompe disease, including in cardiac and skeletal muscle as well as the central nervous system at ASGCT

•
Eight months post infusion, substrate levels were reduced across multiple tissues to levels nearly indistinguishable from healthy mice

•
Read full press release here

Upcoming 2H 2022 Milestones

•
AVR-RD-04 in cystinosis: Plan to engage with regulatory agencies in 2H 2022 to discuss our clinical development and regulatory strategy with the intent of initiating a company-sponsored clinical trial in 2023, subject to regulatory alignment

•
AVR-RD-02 in Gaucher disease:


o
Gaucher disease type 1: Plan to provide interim clinical data update in 2H 2022


o
Gaucher disease type 3: Plan to engage with regulatory agencies on a Phase 2/3 clinical development strategy with aim to initiate a trial in 2023, subject to regulatory alignment

•
AVR-RD-05 in Hunter syndrome: Clinical Trial Application (CTA) authorization expected 2H 2022 with plans to initiate a collaborator-sponsored Phase 1/2 clinical trial in 2023, subject to regulatory alignment

Second Quarter 2022 Financial Results

AVROBIO reported a net loss of $28.1 million for the second quarter of 2022 as compared to a net loss of $31.4 million for the comparable period in 2021. This decrease was driven by a reduction in research and development expenses.

Research and development expenses were $18.9 million for the second quarter of 2022 as compared to $22.5 million for the comparable period in 2021. This decrease was driven by a reduction in program development expenses and personnel-related costs, including non-cash stock-based compensation.

General and administrative expenses were $8.9 million for the second quarter of 2022 as compared to $8.8 million for the comparable period in 2021.

Other (expense) income, net was $0.3 million in expense for the second quarter of 2022 as compared to other (expense) income, net of less than $0.1 million in expense for the comparable period in 2021. This increase was driven by interest expense related to our term loan with Silicon Valley Bank which we entered into during the fourth quarter of 2021.

As of June 30, 2022, AVROBIO had $132.4 million in cash and cash equivalents, as compared to $189.6 million in cash and cash equivalents as of December 31, 2021. Based on AVROBIO’s current operating plan, AVROBIO expects its cash and cash equivalents as of June 30, 2022, will enable AVROBIO to fund its operating expenses and capital expenditure requirements into the first quarter of 2024.

About AVROBIO

Our vision is to bring personalized gene therapy to the world. We target the root cause of genetic disease by introducing a functional copy of the affected gene into patients’ own hematopoietic stem cells (HSCs), with the goal to durably express the therapeutic protein throughout the body, including the central nervous system. Our first-in-class pipeline includes clinical programs for cystinosis and Gaucher disease type 1, as well as preclinical programs for Gaucher disease type 3, Hunter syndrome and Pompe disease. Our proprietary plato® gene therapy platform is designed to be scaled to support late-stage clinical development and commercialization globally. We are headquartered in Cambridge, Mass. For additional information, visit avrobio.com and follow us on Twitter and LinkedIn.

Forward-Looking Statement

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding our business strategy for and the potential therapeutic benefits of our current and prospective product candidates, the expected safety profile of our investigational gene therapies, results of preclinical studies, the design, commencement, enrollment and timing of ongoing or planned clinical trials, clinical trial results, product approvals and regulatory pathways, the timing of patient recruitment and enrollment activities, our plans and expectations with respect to interactions with regulatory agencies and the timing and likelihood of success thereof, the expected benefits and results of our implementation of the plato® platform in our clinical trials and gene therapy programs and its potential impact on our manufacturing and commercialization activities, and statements regarding our financial and cash position and expected cash runway, including impact on anticipated milestones. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.

Any forward-looking statements in this press release are based on AVROBIO’s current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIO’s product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of AVROBIO or our collaborators, the risk that AVROBIO may not successfully recruit or enroll a sufficient number of patients for our clinical trials, the risk that AVROBIO may not realize the intended benefits of our gene therapy platform, including the features of our plato® platform, the risk that our product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving AVROBIO’s product candidates, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, the risk that the size and growth potential of the market for our product candidates will not materialize as expected, risks associated with our dependence on third-party suppliers and manufacturers, including sole source suppliers, risks regarding the accuracy of our estimates of expenses and future revenue, risks relating to our capital requirements and needs for additional financing, risks relating to clinical trial and business interruptions resulting from the COVID-19 outbreak or similar public health crises, including that such interruptions may materially delay our enrollment and development timelines and/or increase our development costs or that data collection efforts may be impaired or otherwise impacted by such crises, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIO’s actual results to differ materially and adversely from those contained in the forward-looking statements, see the section entitled “Risk Factors” in AVROBIO’s most recent Annual or Quarterly Report, as well as discussions of potential risks, uncertainties and other important factors in AVROBIO’s subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Investor Contact:

Christopher F. Brinzey
Westwicke, an ICR Company
339-970-2843
chris.brinzey@westwicke.com

Media Contact:

Kit Rodophele
Ten Bridge Communications
617-999-9620
krodophele@tenbridgecommunications.com

CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)


  
June 30,
    
December 31,
  

 
2022
    
2021
  
             
Cash and cash equivalents
  
$
132,409
    
$
189,567
  
Prepaid expenses and other current assets
    
9,672
      
9,578
  
Property and equipment, net
    
3,618
      
4,126
  
Other assets
    
545
      
566
  
Total assets
  
$
146,244
    
$
203,837
  
                 
Accounts payable
  
$
28
    
$
3,486
  
Accrued expenses and other current liabilities
    
12,757
      
15,900
  
Note payable, net of discount
    
15,104
      
14,945
  
Deferred rent, net of current portion
    
12
      
30
  
Total liabilities
  
$
27,901
    
$
34,361
  
                 
Total stockholders’ equity
    
118,343
      
169,476
  
Total liabilities and stockholders’ equity
  
$
146,244
    
$
203,837
  

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)

   
Three Months Ended June 30,
    
Six Months Ended June 30,
  
   
2022
    
2021
    
2022
    
2021
  
                         
Operating expenses:
                        
Research and development
  
$
18,877
    
$
22,544
    
$
38,130
    
$
41,024
  
General and administrative
    
8,897
      
8,831
      
19,062
      
17,235
  
Total operating expenses
    
27,774
      
31,375
      
57,192
      
58,259
  
                                 
Loss from operations
    
(27,774
)
    
(31,375
)
    
(57,192
)
    
(58,259
)
Other (expense) income, net
    
(280
)
    
(12
)
    
(695
)
    
(27
)
Net loss
  
$ 
(28,054
)
  
$ 
(31,387
)
  
$ 
(57,887
)
  
$ 
(58,286
)
Net loss per share — basic and diluted
  
$ 
(0.64
)
  
$ 
(0.74
)
  
$ 
(1.32
)
  
$ 
(1.39
)
Weighted-average number of common shares outstanding — basic and diluted
    
43,696
      
42,510
      
43,696
      
42,067
  

EX-101.SCH 3 avro-20220809.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 avro-20220809_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Ex Transition Period Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 avro-20220809_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Aug. 09, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 09, 2022
Entity File Number 001-38537
Entity Registrant Name AVROBIO, INC.
Entity Central Index Key 0001681087
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 81-0710585
Entity Address, Address Line One 100 Technology Square
Entity Address, Address Line Two Sixth Floor
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code 617
Local Phone Number 914-8420
Entity Emerging Growth Company true
Entity Ex Transition Period false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol AVRO
Security Exchange Name NASDAQ
XML 7 brhc10040479_8k_htm.xml IDEA: XBRL DOCUMENT 0001681087 2022-08-09 2022-08-09 false 0001681087 8-K 2022-08-09 AVROBIO, INC. DE 001-38537 81-0710585 100 Technology Square Sixth Floor Cambridge MA 02139 617 914-8420 false false false false Common Stock, $0.0001 par value per share AVRO NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 24 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://avrobio.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10040479_8k.htm avro-20220809.xsd avro-20220809_lab.xml avro-20220809_pre.xml brhc10040479_ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10040479_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "brhc10040479_8k.htm" ] }, "labelLink": { "local": [ "avro-20220809_lab.xml" ] }, "presentationLink": { "local": [ "avro-20220809_pre.xml" ] }, "schema": { "local": [ "avro-20220809.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "avro", "nsuri": "http://avrobio.com/20220809", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10040479_8k.htm", "contextRef": "c20220809to20220809", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://avrobio.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10040479_8k.htm", "contextRef": "c20220809to20220809", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001140361-22-028807-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-028807-xbrl.zip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